Harbour BioMed will work alongside BMS to progress and expedite the programmes aimed at the discovery of multi-specific antibodies. Credit: shisu_ka/Shutterstock.com. Harbour BioMed and Bristol Myers ...

The future of electric vehicles depends on battery packs that are safe, efficient, and easy to maintain. Wireless battery-management systems introduce a new way to cover all of these needs. What’s the ...

NEW YORK – Several of its newly acquired precision oncology programs for immunotherapy and radiopharmaceutical candidates are key parts of Bristol Myers Squibb's growth strategy for the coming years, ...

Bristol Myers Squibb and insitro first partnered in 2020 to develop induced pluripotent stem cell models of amyotrophic lateral sclerosis and frontotemporal dementia. Last December, BMS exercised its ...

NEW YORK – Bristol Myers Squibb on Friday said it has inked a deal to purchase RNA drugmaker Orbital Therapeutics for $1.5 billion in cash, bolstering its cell therapy pipeline. Cambridge, ...

On the heels of the launch of an online direct-to-patient (DTP) program offering discounted Eliquis to certain U.S. patients, Bristol Myers Squibb is putting Sotyku at the center of its next DTP ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus erythematosus and plaque psoriasis, and $300 million in funds from Bain Capital.

BioNTech SE and Bristol Myers Squibb have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous ...

Automotive BMS must undergo rigorous testing to verify that it meets stringent performance and safety standards. BMS emulation involves using hardware and software tools to simulate the behavior of a ...

BMS Re, the reinsurance arm of global broker BMS Group, has appointed Brad Melvin (pictured above) as president and chief executive officer of BMS Re US, effective in November. Melvin will report to ...

Hyundai Motor Group (HMG) said it planned to make its battery management system (BMS) available in all its forthcoming electric vehicles (EVs) to alleviate growing concerns over battery safety ...

Bristol Myers Squibb is axing another big bet from the Caforio era, terminating a deal for Agenus’ TIGIT bispecific antibody three years after paying $200 million to buy into the program. Agenus ...